(Q41943954)

14 October 2017

title

Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice (English)

1 reference

14 October 2017

0 references

Dale L Barnard

1

1 reference

14 October 2017

Craig W Day

2

1 reference

14 October 2017

Kevin Bailey

3

1 reference

14 October 2017

Matthew Heiner

4

1 reference

14 October 2017

Robert Montgomery

5

1 reference

14 October 2017

Larry Lauridsen

6

1 reference

14 October 2017

Paul K S Chan

7

1 reference

14 October 2017

Robert W Sidwell

8

1 reference

14 October 2017

publication date

1 January 2006

1 reference

Antiviral Chemistry & Chemotherapy

14 October 2017

published in

1 reference

14 October 2017

volume

17

1 reference

14 October 2017

issue

5

1 reference

14 October 2017

page(s)

275-284

1 reference

Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge

14 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Severe acute respiratory syndrome, a pathological immune response to the new coronavirus--implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Coxsackievirus B4 infection of human fetal thymus cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Behavioral effects of mouse interferons-alpha and -gamma and human interferon-alpha in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Potential antivirals and antiviral strategies against SARS coronavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Aetiology: Koch's postulates fulfilled for SARS virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Characterization and inhibition of SARS-coronavirus main protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Managing SARS amidst uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Antiviral drug discovery against SARS-CoV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

10.1177/095632020601700505

21 January 2018

Identifiers

DOI

1 reference

14 October 2017

1 reference